Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.

ABSTRACT:

Background and aims

Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten.

Methods

Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion.

Results

At the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0-228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): r

SUBMITTER: Garcia-Pavia P 

PROVIDER: S-EPMC11646600 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature